# HBM Healthcare Investments

> HBM Healthcare Investments is a VC fund backing Biotechnology. See 214 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Zug, Switzerland
- Total investments: 214
- Last investment: Jun 2026
- Lead investor: 16%
- Last updated: Aug 2026
- Website: http://www.hbmhealthcare.com

HBM Healthcare Investments is a VC fund in Zug focused on Biotechnology and Health Care. As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The companyfocuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

## Contacts

5 contacts available for HBM Healthcare Investments. Shizune tracks 7 team members at HBM Healthcare Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hbm-healthcare-investments-ag?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $9M–$155M |
| Series C | $5.5M–$182M |
| Series D | $20M–$220M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 91 | 43% |
| Health Care | 73 | 34% |
| Medical | 48 | 22% |
| Pharmaceutical | 34 | 16% |
| Therapeutics | 31 | 14% |

35 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 43 | 20% |
| Series C | 38 | 18% |
| Series D | 18 | 8% |
| Series A | 17 | 8% |
| Funding Round | 15 | 7% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 76 | 36% |
| China | 7 | 3% |
| Switzerland | 7 | 3% |
| Germany | 5 | 2% |
| Israel | 3 | 1% |

18 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Benedikt Suter | Secretary to the Board | 0 | https://shizune.co/investors/profile/benedikt-suter |
| Mario G. Giuliani | Member of the Board of Directors | 0 | https://shizune.co/investors/profile/mario-g-giuliani |
| Andreas Wicki | CEO | 7 | https://shizune.co/investors/profile/andreas-wicki |
| Erwin Troxler | CFO | 0 | https://shizune.co/investors/profile/erwin-troxler |
| Hans Peter Hasler | Chairman, Board of Directors | 0 | https://shizune.co/investors/profile/hans-peter-hasler |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Lycia Therapeutics | Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA. | $75M | Series D | Jun 25, 2026 |  |
| CellCentric | CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer. | $220M | Series D | May 06, 2026 |  |
| SnapCare | SnapNurse provides the only technology platform for quality nurses and medical professionals to find short term engagements without the hassle of paperwork and job boards, as well as allowing medical facilities to find the most relevant staff instantly. |  | Series A | Apr 29, 2026 |  |
| Perspective Therapeutics | Perspective Therapeutics is dedicated to finding the best ways to deliver remedies to patients and their medical needs, and they believe in a targeted, individualized approach to cancer treatment. We design treatments that are given exactly where the doctor needs them. | $175M | Post-IPO Equity | Feb 02, 2026 |  |
| ALX Oncology | ALX Oncology is a preclinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. It is an independent, private biotechnology company.The founding of Alexo Therapeutics was based upon technology invented by Aaron Ring, K. Christopher Garcia, Kipp Weiskopf, Aron Levin, and Irving Weissman at Stanford University.This discovery involves soluble versions of signal regulatory protein-α (SIRPα) that have been engineered to bind CD47 with significantly greater affinity than natural SIRPα.1. | $150M | Post-IPO Equity | Jan 30, 2026 |  |
| CORXEL Pharmaceuticals | Jixing Pharmaceuticals develops innovative science and medicines to underserved Chinese patients with serious and life-threatening diseases. | $287M | Series D | Jan 22, 2026 |  |
| Parabilis Medicines | Parabilis Medicines is a biopharmaceutical company in the clinical stage that focuses on developing exceptional medications targeting challenging protein structures previously deemed undruggable. Utilizing more than ten years of exclusive data, innovative laboratory techniques, and algorithms based on AI and physics, the company has introduced anovel category of stabilized, cell-penetrating alpha-helical peptides known as Helicons™. These peptides can modulate intracellular proteins that traditional drug modalities cannot reach. | $305M | Series F | Jan 08, 2026 |  |
| Vicore Pharma | Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal. | $48M | Post-IPO Equity | Nov 13, 2025 |  |
| Electra Therapeutics | Electra Therapeutics is a clinical stage biotechnology company developing therapies for cancer and other immunological diseases. | $183M | Series C | Oct 22, 2025 |  |
| Neuron23 | Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. | $96.5M | Series D | Jun 24, 2025 |  |

10 of 214 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 28 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 26 deals together
- [HBM Partners](https://shizune.co/investors/profile/hbm-partners) — VC Fund, 24 deals together
- [RA Capital Management](https://shizune.co/investors/profile/ra-capital-management) — VC Fund, 20 deals together
- [Invus](https://shizune.co/investors/profile/invus) — VC Fund, 15 deals together
- [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital) — VC Fund, 14 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Strong Ventures](https://shizune.co/investors/profile/strong-ventures) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund
- [Kakao Ventures](https://shizune.co/investors/profile/kakao-ventures) — VC Fund

## Featured in investor lists
- [Biotech Investors in Germany](https://shizune.co/investors/biotech-investors-germany)
- [Biotech VC Funds in Germany](https://shizune.co/investors/biotech-vc-funds-germany)
- [Medical Investors in Germany](https://shizune.co/investors/medical-investors-germany)
- [Medical Investors in India](https://shizune.co/investors/medical-investors-india)
- [Medical VC Funds in India](https://shizune.co/investors/medical-vc-funds-india)
- [Health Care Investors in Colombia](https://shizune.co/investors/health-care-investors-colombia)

## FAQ

### What does HBM Healthcare Investments invest in?

HBM Healthcare Investments invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 214 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is HBM Healthcare Investments's check size?

HBM Healthcare Investments typically joins rounds of $9M–$155M at Series B, $5.5M–$182M at Series C and $20M–$220M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds HBM Healthcare Investments participates in.

### How do I contact HBM Healthcare Investments?

Public channels for HBM Healthcare Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at HBM Healthcare Investments?

The team at HBM Healthcare Investments includes Benedikt Suter (Secretary to the Board), Mario G. Giuliani (Member of the Board of Directors) and Andreas Wicki (CEO), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co